Shire's Angus Russell will retire from CEO post in 2013

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Shire's Angus Russell will retire from CEO post in 2013

After 13 years with Shire ($SHPG) and 32 years in the pharmaceutical business, CEO Angus Russell will retire next year. Flemming Ornskov will take over the top spot April 30, after a several-month handover period to ensure a smooth transition. Ornskov now serves as chief marketing officer and global head, strategic marketing for general and specialty medicine, at Bayer. "I've enjoyed every day of my time at Shire," Russell said. "I'm very pleased to have been a part of the growth story of this excellent company and to be leaving it in such great shape for further success." As CEO designate, Ornskov will spend time with all three Shire businesses, with a special focus initially on the specialty pharmaceuticals business. Release | Story


Angus Russell--Shire
Russell will retire from Shire next year.



Joanna Horobin--Verastem
Horobin will serve as chief medical officer.

Biotech

> Verastem ($VSTM) appointed Joanna Horobin as chief medical officer. Release

> Celtaxsys appointed Brett Premack as chief technology officer. Release

> Valent BioSciences appointed Mike Daly as plant manager for its new biorational production facility in Osage, IA. Release

> Osiris Therapeutics ($OSIR) promoted Lode Debrabandere to chief operating officer. Release

> Incyte ($INCY) announced that Jim Daly will become executive vice president and chief commercial officer. Release

> Myos appointed Andrew J. Einhorn as its chief financial officer. Release

> Caprotec Bioanalytics named Jonathan Turner managing director and CEO. Release

> AP Pharma appointed Robert Rosen as senior vice president and chief commercial officer. Story

> Coherus BioSciences appointed George G. Montgomery as CFO. Release

> Solazyme ($SZYM) appointed Jean-Marc Rotsaert as COO. Release

> Accera appointed Joseph Jerkovich as director of marketing. Release

> Sutro Biopharma appointed Jeremy Bender as chief business officer and Aaron K. Sato as vice president of research. Release

Pharma Manufacturing

> Albany Molecular Research ($AMRI) announced that Steven R. Hagen has been promoted to senior vice president of pharmaceutical development and manufacturing. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.